I have posted the similarities before.
The big push from the lowest price level for CYDY was the signing of a partnership deal for leronlimab in the US with a another pharmaceutical company. This is for the HIV indication. HIV looks very promising for them should they and the FDA get on the same page about filing the BLA app. Goalpost keep getting moved. Then Covid hit and they realized through one of their scientific advisors, Dr Bruce Patterson, leronlimab may help Covid. The initial patients who were treated via EIND authorization improved so here we are. Along the way they had some promising early results in cancer patients and other studies getting underway. Lot's going on. They have raised a lot of funds along the way and that has led to these promising trials. Plus the severe covid data is to be released in a few weeks so the market is anticipating news.
The interesting thing is Generex is about where they were in Nov/Dec of last year(2019) now with a few irons in the fire we should have heated up by summer if the NGIO IPO and financing allow. IF, I repeat!
The big push from the lowest price level for CYDY was the signing of a partnership deal for leronlimab in the US with a another pharmaceutical company. This is for the HIV indication. HIV looks very promising for them should they and the FDA get on the same page about filing the BLA app. Goalpost keep getting moved. Then Covid hit and they realized through one of their scientific advisors, Dr Bruce Patterson, leronlimab may help Covid. The initial patients who were treated via EIND authorization improved so here we are. Along the way they had some promising early results in cancer patients and other studies getting underway. Lot's going on. They have raised a lot of funds along the way and that has led to these promising trials. Plus the severe covid data is to be released in a few weeks so the market is anticipating news.
The interesting thing is Generex is about where they were in Nov/Dec of last year(2019) now with a few irons in the fire we should have heated up by summer if the NGIO IPO and financing allow. IF, I repeat!
4
